Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention

Cardiology (Switzerland)

Volumn 122, Issue 3, 2012, Pages 195-202

  Li, Wei ^a   Fu, Xianghua ^a   Wang, Yanbo ^a   Li, Xiangnan ^a   Yang, Zengxin ^a   Wang, Xuechao ^a   Geng, Wei ^a   Gu, Xinshun ^a   Hao, Guozhen ^a   Jiang, Yunfa ^a   Fan, Weize ^a   Wu, Weili ^a   Li, Shiqiang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Acute ST segment elevation myocardial infarction; Atorvastatin; Contrast induced nephropathy; Emergency percutaneous coronary intervention; Renal protection

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATININE; CYSTATIN C; PLACEBO;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CONTRAST MEDIA; CREATININE; CYSTATIN C; EMERGENCY TREATMENT; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MYOCARDIAL INFARCTION; PYRROLES;

EID: 84864408365     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000339472     Document Type: Article

References (27)

1. Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, Sakuma T, Yoshida S, Sutani Y, Iwasaka T: Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2010; 105: 624-628.
2. Zhang B-C, Li W-M, Xu Y-W: High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011; 27: 851-858.
3. Chen SL, Zhang J, Yei F, Zhu Z, Liu Z, Lin S, Chu J, Yan J, Zhang R, Kwan TW: Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol 2008; 126: 407-413. (Pubitemid 351636362)
4. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, D'Ambrosio A, Covino E, Di Sciascio G: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMS (atorvastatin for reduction of myocardial damage during angioplasty-cell adhesion molecules) substudy. J Am Coll Cardiol 2006; 48: 1560-1566. (Pubitemid 44528186)
5. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G: Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (atorvastatin for reduction of myocardial dysrhythmia after cardiac surgery) study. Circulation 2006; 114: 1455-1461. (Pubitemid 44526999)
6. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A, Di Sciascio G: Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention from the ARMYDA-CIN (atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy) trial. Am J Cardiol 2011; 108: 1-7.
7. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 2004; 110: 674-678. (Pubitemid 39056265)
8. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278. (Pubitemid 46467240)
9. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDArecapture (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial. J Am Coll Cardiol 2009; 54: 558-565.
10. Goldenberg I, Matetzky S: Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005; 172: 1461-1471. (Pubitemid 40803495)
11. Wong PC, Li Z, Guo J, Zhang A: Pathophysiology of contrast-induced nephropathy. Int J Cardiol 2012; 158: 186-192.
12. Wang YX, Jia YF, Chen KM, Morcos SK: Radiographic contrast media induced nephropathy: Experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001; 74: 1103-1108. (Pubitemid 34071332)
13. Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T: Renal protective effects and the prevention of contrastinduced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 2009; 53: 1040-1046.
14. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, Wu W, Fan W, Su J, Hao G, Jiang Y, Xue L: B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiol 2010; 51: 641-648.
15. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148: 284-294. (Pubitemid 351665489)
16. McCullough PA, Tumlin JA: Prostaglandinbased renal protection against contrast-induced acute kidney injury. Circulation 2009; 120: 1749-1751.
17. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G: Impact of high-dose n-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (prospective, single-blind, placebo-controlled, randomized Leipzig immediate percutaneous coronary intervention acute myocardial infarction NACC) trial. J Am Coll Cardiol 2010; 55: 2201-2209.
18. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, Isono T, Sutani Y, Yuasa F, Iwasaka T: A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol 2011; 107: 1604-1608.
19. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849. (Pubitemid 41097461)
20. Attallah N, Yassine L, Musial J, Yee J, Fisher K: The potential role of statins in contrast nephropathy. Clin Nephrol 2004; 62: 273-278. (Pubitemid 39386803)
21. Zhao JL, Yang YJ, Zhang YH, You SJ, Wu YJ, Gao RL: Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008; 126: 435-436.
22. Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, Sugiura T, Iwasaka T: Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009; 54: 192-198.
23. Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD: Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology 2010; 15: 165-170.
24. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, Bal U, Ozin B: Prevention of contrast-induced impairment of renal function by short-term or longterm statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 2010; 21: 750-757.
25. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R: Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010; 61: 711-714.
26. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS: Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J 2008; 155: e491-498.
27. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F: Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105: 288-292.